newsletter masthead
October 17, 2018
MEMBER/CENTER HIGHLIGHTS
Eng Receives Prestigious Medal of Honor from American Cancer Society
Charis Eng, MD, PhD, chair of  Cleveland Clinic's Genomic Medicine Institute and member of the Case Comprehensive Cancer Center, is receiving the American Cancer Society's Medal of Honor, the organization's highest award.  An internationally recognized physician-scientist in the cancer genetics field, Dr. Eng is among five honorees to receive the award at a ceremony in Washington, D.C. on October 18.

Dr. Eng  is being honored for clinical research - contributions, specifically in genomic medicine research, which have significantly improved the clinical outcome of patients. In her dual role as Founding Chair of the Genomic Medicine Institute and Founding Director of the Center for Personalized Genetic Healthcare, she continues to implement evidence-based genetic- and genomics-enabled personalized healthcare that has enhanced care for patients at genetic risk of disease nationally and globally. "Through educating physicians and promoting genetic counseling and smart clinical management," said Dr. Eng, "we can improve early diagnosis and develop the most targeted cancer treatment possible for individual patients."

The ACS Medal of Honor is presented to individuals who have made outstanding and valuable contributions in the field of cancer. This year's other recipients are The Honorable Joseph R. Biden Jr., Emmanuelle Charpentier, PhD, Jennifer Doudna, PhD, and Michael J. Thun, MD. Past honorees include U.S. President and First Lady George H.W. Bush and Barbara Bush; U.S. Senator Edward M. Kennedy; George Papanicolau, MD, inventor of the Pap test; Judah Folkman, MD, a leading researcher in the field of antiangiogenesis; and Former U.S. Surgeon General C. Everett Koop, MD. more>
University Hospitals Seidman Cancer Center Becomes First in U.S. To Use Newly FDA-Approved Drug That Makes Brain Tumors Glow Hot Pink
The drug 5-Aminolevulinic Acid (5-ALA), which helps neurosurgeons see the edges of a tumor more clearly to improve removal, was used in brain cancer surgery at University Hospitals Seidman Cancer Center for the first time since the FDA approved it for use in the United States.  Although the drug has long been a standard of care in Germany and much of Europe, it was only approved by the FDA for use in the U.S. in 2017.

Andrew Sloan Andrew Sloan, MD, Director, Brain Tumor and Neuro-Oncology Center at UH Seidman and UH Cleveland Medical Center, Case Comprehensive Cancer Center, who has been doing  clinical trials with the drug for almost a decade based on his own FDA-approved IND clinical trial, was the first neurosurgeon in the U.S. to use the drug on a patient with brain cancer since FDA approval. more>
New Options for Breast Cancer Drug Development Found in Estrogen Receptors
Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually develop drug resistance, leaving doctors desperate for alternatives. Now, researchers from Case Western Reserve University School of Medicine have uncovered a previously uncharacterized, bridge-like structure within the human estrogen receptor that could serve as a valuable new drug target. In  Nature Communications , researchers describe a "burning the bridge" strategy to disrupting the estrogen receptor, and how to screen breast cancer drugs designed to do it.

Yang, Sichun "Until now, the structure of the entire estrogen receptor complex was unknown, so it was a challenge to identify novel or functionally important target sites for new drugs," said Sichun Yang, PhD, senior author on the study and associate professor of nutrition, proteomics, pharmacology, and biophysics at Case Western Reserve University School of Medicine. "The structures of individual receptor pieces were known, but how they fit together was a mystery. Our study identified a novel interface that bridges the two major functional units of the receptor."

Yang, who is also a member of the Case Comprehensive Cancer Center, and colleagues integrated genetic engineering, proteomics, and computer modeling to reveal the full estrogen receptor structure. It is the first application of an approach the researchers developed and termed iSPOT (integration of Scattering, footPrinting, and dOcking simulaTion). The study was a collaborative effort between Case Western Reserve, Argonne National Laboratory, and Lawrence Berkeley National Laboratory. Yang led the study alongside Case Western Reserve colleagues Hung-Ying Kao, PhD, professor of biochemistry, and Mark Chance, PhD, vice dean for research and Charles W. and Iona A. Mathias Professor of Cancer Research. more>
Khalil Invited as Session Organizer for International Symposium 
Ahmed Khalil Ahmad M. Khalil, PhD, Assistant Professor of Genetics and Genome Sciences and member, Case Comprehensive Cancer Center, was invited to be a session organizer for the 18th  Chinese-American Kavli Frontiers of Science Symposium,  October 19-21 in Nanjing, China. 

The Chinese-American Kavli Frontiers of Science symposia are sponsored by the U.S. National Academy of Sciences and the Chinese Academy of Sciences. The symposium brings together outstanding young scientists to discuss exciting advances and opportunities in a broad range of disciplines.
MARK YOUR CALENDARS
3rd Annual Cancer Disparities Symposium
Mar 1, 2019 | Tinkham Veale University Center
Disparities Banner 2019-final
The 3rd Annual Cancer Disparities Symposium will be held Friday, Mar 1, 2019. 

2019 Symposium Highlights
  • Keynote presentations by renowned disparities researchers and community leaders
    • Opening Keynote by Eliseo J. PĂ©rez-Stable, MD, Director of the National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH)
    • Scientific Keynote presentation by Rick Kittles, PhDAssociate Director of Health Equities, Comprehensive Cancer Center; Professor and Director, Division of Health Equities, Department of Population Sciences, City of Hope
  • Oral and Lightning presentations from selected abstracts
  • Poster session highlighting academic research and community programs
  • Networking session
  • All attendee forum
Call for Abstracts

The Case Comprehensive Cancer Center invites multidisciplinary researchers, community agencies and organizations to submit abstracts for presentation at the 3rd Annual Cancer Disparities Symposium. Abstracts will be divided into two tracks: Scientific Research and Community Programs. Meritorious abstracts will be selected for oral presentations. 

Abstracts must be submitted via email ( caseccc-ocdr@case.edu) by 5pm EST on December 21, 2018.

Cancer Center Seminar Series: "Metabolic reprogramming in pancreatic cancer"
Oct 19, 12p | WRB 1-413

Jordan Winter Join us Friday, October 19 at 12p in the WRB 1-413 to hear Jordan Winter, MD present " Metabolic reprogramming in pancreatic cancer." Dr. Winter is Associate Professor of Surgery, Case Western Reserve University School of Medicine; Chief, Division of Surgical Oncology, University Hospitals Cleveland Medical Center; and Member, Case Comprehensive Cancer Center. This seminar is p resented by the GI Cancer Genetics Program of the Case Comprehensive Cancer Center. 

Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer with a long-term survival rate under 10%. Available cytotoxic chemotherapies have significant side effects, and only marginal therapeutic efficacy in patients with advanced disease.  FDA approved drugs currently used against PDA target DNA metabolism, DNA synthesis or DNA repair. However, alternative metabolic targets beyond DNA may prove to be much more effective. PDA cells are forced to live within a unique microenvironment characterized by relative hypovascularity, hypoxia, and nutrient deprivation. Thus, PDA cells must exhibit molecular strategies to adapt to severe metabolic conditions. A better understanding of the metabolic dependencies required by PDA to survive and thrive within the harsh metabolic milieu could reveal metabolic vulnerabilities which can be targeted therapeutically. Since normal cells are well perfused, therapies designed to exploit these adaptive changes will likely have a clinically significant therapeutic window. Recent work has uncovered a number of promising therapeutic targets in the metabolic domain, and clinicians are already translating some of these discoveries to the clinic. Basic biologic insights will likely yield novel therapeutic strategies with promise against this aggressive and chemotherapy resistant tumor.
Midwest Association of Core Directors Annual Meeting
Oct 24-26, 2018 | Tinkham Veale University Center
Midwest Association of Core Directors Case Western Reserve University (CWRU) School of Medicine and Cleveland Clinic Lerner Research Institute (LRI) is hosting the 9th annual meeting of the Midwest Association of Core Directors, the regional chapter of the Association of Biomolecular Resource Facilities.

Program Highlights
  • Newest Highlights in Shared Resources Technology & Expertise: Introductory ("101-level") and State of the Science level breakout meetings on Genomics, Mass Spec, Imaging, Administration, Drug Discovery, Entrepreneurship, and RNA Sciences.
  • Satellite Workshops: Option to attend a pre and/or post Satellite Workshop, made possible by supporting Platinum Plus Level Sponsors FEI Thermo Fisher and Ilumina.
  • Core Facility Tours: Pre-conference Core Facility Tours of Cleveland Clinic or Case Western University Research Sites.
  • Tour Microsoft HoLoLens Facility: Limited space to sign up for a unique peek at the Microsoft HoLoLens Facility at CWRU! Only 20 people will be able to see this unique 'lens' into medical education using holographic technology.
Who Should Attend?
All members of the research community are encouraged to attend this conference to learn how core facilities can move your science ahead! 

Registration Discount for CWRU SOM Employees
CWRU School of Medicine Office of Research Administration will cover 50% of the registration fee for CWRU SOM employees. Contact Matt DeVries
( mpd35@case.edu) for discount code!
FUNDING OPPORTUNITIES
Limited Submission: Nominations for F99/K00 Award for Training Predoctoral/Postdoctoral Transitions
INTERNAL DEADLINE: Nov 25, 2018
DEADLINE TO SUBMIT LOI TO NIH: Jan 22, 2019
PROPOSAL SUBMISSION DEADLINE: Feb 22, 2019
NCI logo The NCI has announced a  Request for Applications for the Predoctoral to Postdoctoral Fellow Transition (F99/K00) Award for 2019, to support outstanding PhD candidates as they complete their dissertation research training (F99 phase; 1-2 years) and transition to a mentored and research-intensive, cancer-focused postdoctoral career development research positions (K00 phase - up to 4 years). Projects must be clearly focused on cancer and developing a research-intensive career.

To apply for this award, an applicant must be nominated by their institution. As each institution is allocated only one nomination, the Case Comprehensive Cancer Center (Case CCC) requires potential applicants to assemble a pre-application for review and selection of the candidate. 

Eligibility
  • Open to 3rd or 4th year PhD students, including F31 Fellowship applicants and current awardees (3rd or 4th-year students would have matriculated in 2015 or 2016).
  • International students may apply.
  • Students in a dual-degree program (e.g. MD/PhD, DO/ PhD , DDS/ PhD , or DVM/ PhD ) are not eligible.
Limited Submission - NSF: Major Research Instrumentation Program (MRI)
CWRU Internal Deadline: Oct 26, 2018
External Deadline: Jan 22, 2019
NSF logo The Major Research Instrumentation (MRI) Program serves to increase access to multi-user scientific and engineering instrumentation for research and research training in our Nation's institutions of higher education and not-for-profit scientific/engineering research organizations. An MRI award supports the acquisition or development of a multi-user research instrument that is, in general, too costly and/or not appropriate for support through other NSF programs.

MRI provides support to acquire critical research instrumentation without which advances in fundamental science and engineering research may not otherwise occur. MRI also provides support to develop next-generation research instruments that open new opportunities to advance the frontiers in science and engineering research. Additionally, an MRI award is expected to enhance research training of students who will become the next generation of instrument users, designers and builders.

Applicants should consult with their Associate Deans for Research prior to internal submission to assure they meet eligibility criteria and to obtain approval of cost-share and facilitization.
2019 Core Facility Investment RFI 
Deadline Extended: Oct 29, 2018

CWRU SOM logo - png In 2016, School of Medicine leadership charged the 
Core Facilities Steering Committee (CSC) with creating and curating a ranked list for University Investment in Shared Resource and Core Facility technology. To that end, the CSC solicited responses to a Request for Information (RFI) from Core Facility Directors proposing new technologies and upgrades to existing technologies that would propel our research community forward. From the 29 proposals submitted, a list of 10 new technologies was compiled and used by School Leadership in the ensuing years to procure 6 of the 10 instruments through a combination of direct SOM funds, Major Center agreements, and S10 grants.

Due to the success of this project, we are pleased to announce the 2019 Core Facility Investment RFI. This RFI is open to all SOM faculty member partnered with a  Core Director or faculty looking to be a  Core Director in a new service line.  

Contact Matt  DeVries ( mpd35@case.edu) for more information.
IN THE NEWS
Parade - Oct 12, 2018
This year, about 1.7 million people will hear the words, "You have cancer." Yet more and more are surviving: In 2016, there were 15.5 million cancer survivors in the U.S., and that number is expected to rise to 20.3 million by 2026... Now, results from  a groundbreaking study , known as the TAILORx trial, found that hormone therapy might be all that is necessary to treat 70 percent of women with the most common form of breast cancer, saving women unnecessary side effects like fatigue, hair loss, nausea, vomiting and anemia.  " This means a large number of patients can safely avoid chemotherapy," says Jame Abraham, MD, director of Cleveland Clinic's Breast Oncology Program. "We can really individualize treatment and make sure we are prescribing the right treatment for the right purpose."
NIH BULLETIN- Notices and Funding Opportunities
rfas 
Notices
Request for Information (RFI): Challenges and Opportunities for Understanding and Treating Small Cell Lung Cancer (NOT-CA-19-001)

Reinstatement of NIH SBIR Direct-to-Phase II Authority and Associated Updates to PAR-18-303 Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44 Clinical Trial Not Allowed)(NOT-CA-19-002)

Reinstatement of NIH SBIR Direct-to-Phase II Authority and Associated Updates to PAR-18-801 Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R43/R44 - Clinical Trial Optional)(NOT-CA-19-003)

Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study Funding Opportunity Announcement - Coordinating Center (U24 - Clinical Trial Not Allowed)(NOT-DA-18-031)

Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition Adolescent Brain Cognitive Development (ABCD) Study Funding Opportunity Announcement - Research Project Sites (U01 - Clinical Trial Not Allowed)(NOT-DA-18-032)

Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition Adolescent Brain Cognitive Development (ABCD) Study Funding Opportunity Announcement - Data Analysis, Informatics, and Resource Center (U24)(NOT-DA-18-033)

Program Announcements
High or Medium Priority AIDS Research on Non-AIDS-Defining or AIDS-Defining Cancers (R21)(PA-16-425)

High or Medium Priority AIDS Research on Non-AIDS-Defining or AIDS-Defining Cancers (R01)(PA-16-426)
IN THIS ISSUE
EVENTSevents
Thurs, Oct 18
Developmental Therapeutics Journal Club
9a R4-013

Biochemistry Harland G. Wood Distinguished Lecture
Bryan Roth, MD, PhD
Professor, Division of Chemical Biology
University of North Carolina at Chapel Hill
Director, NIMH Psychoactive Drug Screening Program
"How drugs bind to and activate G protein coupled receptors "
3p SOM E401
Fri, Oct 19
Taussig Cancer Institute Grand Rounds:  Bruell Lecture
Shirish Gadgeel, MD University of Michigan "Eclectic lung cancer clinical research projects"
8a CA5-120

Cancer Center Seminar Series
Jordan Winter, MD, FACS
Associate Professor, Surgery, CWRU
Chief, Division of Surgical Oncology, UHCMC
Member, GI Cancer Genetics  Program, Case CCC
"Metabolic reprogramming in pancreatic cancer"
12p WRB 1-413
Mon, Oct 22
Cancer Center Research Chalk Talk
Zhenghe John Wang, PhD
Professor/Vice Chair for Faculty Development, Genetics and Genome Sciences, CWRU
Co-Leader, GI Cancer Genetics Program, Case CCC
1p WRB 3-136
Tues, Oct 23
Cancer Imaging Monthly Meeting
Chris Flask, PhD
Associate Professor, Radiology, CWRU
Director, Imaging Research Shared Resource; Member,  Cancer Imaging Program, Case CCC
1:30p Wearn B37
Thurs, Oct 25
Developmental Therapeutics Journal Club
9a R4-013

Molecular Biology and Microbiology Seminar
Tomoaki Ogino, PhD
Assistant Professor, Molecular Biology and Microbiology, CWRU
"Molecular mechanisms of de novo  transcription initiation by non-segmented negative strand RNA viral polymerases"
1p SOM W203
Fri, Oct 26
Taussig Cancer Institute Grand Rounds
8a CA5-120

Department of Cellular and Molecular Medicine
Hanrui Zhang, PhD
Assistant Professor, Columbia University
"Linking human macrophage biology to cardiometabolic diseases: functional genomics integrating iPS cells and CRISPR technologies"
10a NC1-202

Cancer Center Seminar Series 
Yong Li, PhD
Professor, Molecular Medicine; Staff, Cancer Biology, CWRU/Cleveland Clinic
"p53 and Roundup: Genetic and environmental risk for cancer"
12p WRB 1-413

ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
prev-funding
PREVIOUSLY ANNOUNCED OPPORTUNITIES

Deadline: Open

Deadline: Open

Deadline: Open
Case Comprehensive Cancer Center 
2103 Cornell Road, Ste 1422
Cleveland, OH 44106-7285